Alkem appoints two senior managers as Alkem stock nears its yearly low

Published on 10/20/2026 at 04:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alkem added two senior managers on October 12, 2026. Alkem stock stood at INR 4,995.00 on October 19, 2026, 0.40 percent above INR 4,975.05.

Operating picture and valuation

Alkem appointed two senior managers on October 12, 2026.
First-quarter revenue reached INR 37.40 billion, up 11.00 percent year over year.
Alkem stock stood at INR 4,995.00 on October 19, 2026, 0.40 percent above its 52-week low.
Motilal Oswal retained a Neutral rating and set an INR 5,770.00 target on August 15, 2026.

Alkem, INE540L01014, Illustration mit AI erstellt.

Alkem (ISIN INE540L01014) appointed two senior managers on October 12, 2026, while its latest BSE quote was INR 4,995.00 on October 19, 2026 at 3:28 p.m. IST. According to Sharpely, Laxmikant Tiwari and Nilesh Vartak joined the company's senior management.

Management changes meet a weak chart

The appointment came as the stock traded only 0.40 percent above its INR 4,975.05 52-week low on October 19, 2026. The same quote showed a 52-week high of INR 5,933.00, leaving the share 15.80 percent below that level.

Market capitalization stood at INR 598.1 billion on October 19, 2026. The valuation picture therefore combines a large listed Indian pharmaceutical business with a share price close to its yearly floor.

What does the margin mix mean?

Alkem's first-quarter FY27 revenue rose 11.00 percent year over year to INR 37.40 billion, broadly above Motilal Oswal's INR 37.14 billion estimate. Adjusted profit after tax fell 20.40 percent year over year to INR 5.20 billion, although it was 19.00 percent above the broker's estimate, according to DSIJ.

The margin split is important for interpreting that result. Gross margin expanded to 67.90 percent in the first quarter of FY27, while adjusted EBITDA margin declined to 20.50 percent as other expenses, employee costs and newer CDMO investments absorbed part of the gross-margin gain. DSIJ reported that Motilal Oswal expected those investments to weigh on FY27 earnings.

Three dated developments

Sharpely lists three recent developments: Alkem reported first-quarter FY27 revenue of INR 37.40 billion on August 14, 2026; it launched NeuCeno on September 16, 2026; and it disclosed the appointment of a chief financial officer successor process on September 24, 2026. The current management appointment followed on October 12, 2026.

The next dated item in the recent filing record is the October 15, 2026 Q2 preview, which pointed to domestic demand support and continuing US pricing pressure. That combination makes earnings quality and international pricing the key operating variables for the next report.

Stock near its yearly low

Motilal Oswal retained a Neutral rating and set an INR 5,770.00 target on August 15, 2026, according to DSIJ. The target was 15.51 percent above the INR 4,995.00 BSE price, but the broker also cited weak trade generics, a longer CDMO breakeven period and delayed biosimilar approvals as constraints.

The last available quote was INR 4,995.00 on BSE on October 19, 2026 at 3:28 p.m. IST, placing Alkem stock 0.40 percent above its INR 4,975.05 52-week low.